Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127200351 | 12720035 | 1 | I | 20160901 | 20160907 | 20160907 | EXP | PHHY2016BR122848 | NOVARTIS | 0.00 | F | Y | 0.00000 | 20160907 | MD | BR | BR |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127200351 | 12720035 | 1 | PS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | 13.3 MG, QD PATCH 15 (CM2) | Y | 22083 | 13.3 | MG | TRANS-THERAPEUTIC-SYSTEM | QD | |||||
127200351 | 12720035 | 2 | SS | EXELON | RIVASTIGMINE TARTRATE | 1 | Oral | 1 DF, QD | 0 | 1 | DF | TABLET | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
127200351 | 12720035 | 1 | Dementia Alzheimer's type |
127200351 | 12720035 | 2 | Dementia Alzheimer's type |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
127200351 | 12720035 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
127200351 | 12720035 | Application site hypersensitivity | |
127200351 | 12720035 | Application site irritation | |
127200351 | 12720035 | Cardiac disorder | |
127200351 | 12720035 | Eating disorder | |
127200351 | 12720035 | Lack of application site rotation | |
127200351 | 12720035 | Malaise | |
127200351 | 12720035 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |